Biofrontera engages Lytham Partners for strategic investor relations and communication.

Biofrontera has engaged Lytham Partners to lead a strategic investor relations and shareholder communication program. Lytham Partners has over 20 years of experience and a large network of institutional investors. The program aims to increase exposure to investors and improve corporate and shareholder communications.

Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in photodynamic therapy (PDT), has appointed Lytham Partners to lead its strategic investor relations and shareholder communication program. This move comes after Biofrontera completed several transformative actions, including restructuring its relationship with its former parent company, acquiring U.S. intellectual property and new drug applications, taking control of manufacturing, and securing $11 million in new funding.

Lytham Partners, with over two decades of experience, is one of the leading investor relations firms in the country. The firm has established a vast network of institutional investors and developed a platform that facilitates consistent and in-depth exposure to investors through various communication channels. This partnership aims to increase Biofrontera's investor base and enhance its corporate and shareholder communications.

Dr. Hermann Luebbert, CEO and Chairman of Biofrontera, commented, "Through a series of transformative actions, we have positioned Biofrontera to achieve meaningful profitability in the quarters ahead. Engaging Lytham Partners at this stage is ideal to broaden our investor base and ensure our value proposition is fully recognized by the market."

Ben Shamsian, Vice President of Lytham Partners, stated, "Biofrontera has made tremendous progress in recent months, establishing a strong foundation to become a leading U.S. specialty dermatology company. We look forward to introducing Biofrontera to our platform of investors and supporting best practices within their communications program at all levels."

This strategic move by Biofrontera is aimed at increasing investor awareness and engagement, which is crucial for a biopharmaceutical company like Biofrontera that is focused on developing innovative therapies for dermatological conditions.